EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Illumina's Enterprise Value is $31,665 Mil.
Illumina's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 was $208 Mil. Therefore, Illumina's EV-to-FCF for today is 152.24.
The historical rank and industry rank for Illumina's EV-to-FCF or its related term are showing as below:
ILMN'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.69 Med: 54.82 Max: 283.94
Current: 152.24
During the past 13 years, the highest EV-to-FCF of Illumina was 283.94. The lowest was 10.69. And the median was 54.82.
ILMN's EV-to-FCF is ranked worse than 95.58% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.57
vs ILMN: 152.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-06-27), Illumina's stock price is $193.35.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $4.600. Therefore, Illumina's PE Ratio for today is 42.03.
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina EV-to-FCF Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Illumina's EV-to-FCF falls into.
Illumina's current Enterprise Value is $31,665 Mil.
Illumina's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $208 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (NAS:ILMN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Illumina's share price for today is $193.35.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Illumina EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Illumina's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.58(0.3%) Volume: 1,387,917 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
